LONA:NASDAQ
LeonaBio Inc
$7.70
arrow_upward
+0.39%(+0.030) 1D
Sep 3, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LONA...
Open
$7.59
High
$8.07
Low
$7.54
Mkt. cap
72.55M
Avg. vol.
42.58K
Volume
7.64K
52-wk high
$14.19
52-wk low
$4.22
EPS
-$19.72
Beta
2.05
Shares outstanding
9.42M
No. of employees
19
Open
$7.59
High
$8.07
Low
$7.54
Mkt. cap
72.55M
Avg. vol.
42.58K
Volume
7.64K
52-wk high
$14.19
52-wk low
$4.22
EPS
-$19.72
Beta
2.05
Shares outstanding
9.42M
No. of employees
19
News stories
From web sources and news partners
Stock Titan
·
13 hours ago
A drug developer's New York fireside chat is set for Sept. 11
TradingView
·
3 days ago
Sermonix Pharmaceuticals Discloses Investment at LeonaBio, Inc. with 36.9% Stake
Profile
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
About LeonaBio Inc
CEO-
Employees19
Founded2011
HeadquartersBothell, Washington, United States
SectorPharmaceutical industry
Websiteleonabio.com